Table III.
Univariate and multivariate Cox regression analysis of recurrence-free survival of patients with breast cancer.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Parameters | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age (≥50 vs. <50 years) | 0.979 (0.589–1.629) | 0.936 | ||
| Menopausal status (pre vs. post) | 1.047 (0.631–1.739) | 0.859 | ||
| Tumor size (≥2 vs. <2 cm) | 1.011 (0.591–1.729) | 0.968 | ||
| Lymph node status (negative vs. positive) | 1.999 (1.205–3.317) | 0.007 | 1.421 (0.703–2.872) | 0.328 |
| TNM (stage I+II vs. III) | 1.471 (1.038–2.085) | 0.030 | 0.992 (0.703–2.872) | 0.328 |
| ER status (negative vs. positive) | 1.024 (0.611–1.717) | 0.927 | ||
| PR status (negative vs. positive) | 0.997 (0.600–1.655) | 0.989 | ||
| HER2 status (negative vs. positive) | 1.268 (0.764–2.103) | 0.358 | ||
| BANCR (high vs. low) | 1.575 (1.317–1.883) | <0.001 | 1.532 (1.272–1.844) | <0.001 |
HR, hazard ratio; CI, confidence interval; BANCR, BRAF-regulated lncRNA 1; TNM, Tumor-Node-Metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.